Torrent’s manufacturing facility at Indrad, Gujarat, was set up in 1989. Today, the Indrad facility is at par with international standards. It complies with WHO, cGMP, MHRA and TGA norms and has received ISO 9001, ISO 14001 and OHSAS 18001 (Occupational Health and Safety Management System) certifications; adequately reflecting Torrent’s commitment towards quality and safety. Attainment of such standards have also opened the key to gaining footholds in regulated, lucrative markets like the US and EU for Torrent Pharma.
Torrent firmly believes that quality can not be talked into a product, but has to exist inherently. Its efforts towards realizing world-class quality standards came into limelight with the “Quality Excellence Gold Award” received from the Indian Drug Manufacturers’ Association (IDMA) for four consecutive years viz. 2000, 2001, 2002 and 2003.
- Land - 178,000 sq. metres
- Built-up Area - 50,000 sq. metres for Formulations, 10,000 sq. meters for API
- Excellent Support Services
- Finished Products - Oral Dosage Form, Injectables, Freeze Dried Sterile Injections
- API - Multi Product, Versatile Facility, Upgraded to International Standards
- Hygiene Zones – Process step dependent special zones created for each type of activity
Manufacturing Capacities (per annum) ::
| Formulations - Tablets, capsules and vials
|| 6,000 million
| Bulk Drugs/API
|| 15,000 kg
Tie-up with Novo Nordisk ::
We have signed an agreement with Novo Nordisk India in August 2005 and part of our parenteral facility is dedicated for the formulation and packaging of Insulin, exclusively for Novo Nordisk. The facility will cater to the increased demand for Novo Nordisk Insulin products in India and will incorporate state of art technology in formulation, filling, inspection and packaging of Novo Nordisk insulin formulations.
This facility will have the requisite flexibility to expand and the production will be done with the same state of the art technology and quality standards as practiced across the world by Novo Nordisk.
We have been manufacturing Insulin for Novo Nordisk’s India requirement for more than 15 years now. Our parenteral site for insulin production is dedicated for Novo Nordisk products, and complies with their worldwide norms.